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BACKGROUND: The combination of sorafenib (vascular endothelial growth factor receptor 2 inhibitor) and sirolimus (mammalian target
of rapamycin inhibitor) might work synergistically.
METHODS: A phase I dose-escalation study with sorafenib twice a day (b.i.d.) and sirolimus once daily (q.d.) was performed to
determine the recommended dose of the combination in patients with solid tumours. Secondary objectives were to determine the
safety profile and maximum tolerated dose (MTD), and to evaluate the pharmacokinetics (PK) of the combination.
RESULTS: Dose-limiting toxicities were transaminitis and cutaneous toxicity. The most frequently reported adverse events were
elevated transaminases, hypophosphatemia, fatigue, anorexia, diarrhoea, nausea, rash and palmar–plantar erythrodysaesthesia.
Sirolimus did not change the PK of sorafenib; in contrast, sorafenib reduced the AUC(0 96) and Cmax of sirolimus. No objective
responses were observed; eight patients showed stable disease for a median of 16.3 weeks (range 8–24). The MTD of the
combination was sorafenib 200mg b.i.d. with sirolimus 1mg q.d.
CONCLUSION: The combination of sorafenib and sirolimus showed enhanced toxicity, which could not be explained by the PK of both
drugs. The relative low doses at the MTD, in combination with the PK results, do not warrant further development of this
combination.
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Multiple signalling pathways contribute to tumour growth and
development. Single-agent strategies with small molecule signal
transduction inhibitors or antibodies against one of these targets
have shown clinical activity in several tumour types, although, only
modest prolongation of overall survival has been shown. Combin-
ing agents that target pathways at multiple sites may enhance anti-
tumour activity by biochemical and clinical synergism, reduce
drug resistance or be successful with lower doses resulting in less
toxicity (Dent et al, 2009). Sorafenib inhibits the receptor tyrosine
kinases, vascular endothelial growth factor receptor 2 (VEGFR2),
VEGFR3, Fms-related tyrosine kinase 3, c-KIT, platelet-derived
growth factor receptor, and threonine kinases B-RAF and C-RAF.
Sorafenib inactivates the RAS-RAF-MEK-ERK pathway, with sub-
sequent inhibition of tumour-cell proliferation and angiogenesis.
It has been approved for the second-line treatment in metastatic
renal-cell cancer and hepatocellular carcinoma. The recommended
dose of sorafenib is 400mg twice daily (b.i.d.) in metastatic renal-
cell cancer. Sirolimus is an orally administered mammalian target
of rapamycin (mTOR) inhibitor and is the active metabolite of
intravenously administered temsirolimus, registered for first-line
treatment in poor prognosis metastatic renal-cell cancer.
The threonine kinase mTOR is a key element of the intracellular
signalling pathways involved in tumour cell proliferation, growth,
survival and angiogenesis. Its activation leads to progression
from the G1 to S phase of the cell cycle (Abraham and Gibbons,
2007). Mammalian target of rapamycin is activated aberrantly in
tumours. This activation is increased by several signalling path-
ways, including the phosphatidyl-inositol 3-kinase/Akt, epidermal
growth factor, Ras/mitogen-activated protein kinase pathways
(Meric-Bernstam and Gonzalez-Angulo, 2009). One of the most
important downstream proteins affected by mTOR is hypoxia-
induced factor 1a. Hypoxia-induced factor 1a is a transcription
factor, essential for the expression of genes necessary for cell
growth in hypoxic conditions, as in tumours. Transcription of
VEGF gene is regulated by hypoxia-induced factor 1a (Forsythe
et al, 1996). Mammalian target of rapamycin is an attractive target
for anti-cancer therapy. Sirolimus is approved as an immuno-
suppressive agent indicated for the prophylaxis of organ rejection
in renal transplant patients. Currently sirolimus is studied in
several types of cancer at doses of 0.5–10mg orally daily (Stallone
et al, 2005; Reardon et al, 2006; Rizell et al, 2008).
Combined inhibition of the VEGFR- and mTOR- signalling
network may work synergistically. During treatment with a VEGFR
inhibitor, such as sorafenib, plasma levels of VEGF will increase,
which may contribute to resistance (Sosman and Puzanov, 2009).
By addition of an mTOR inhibitor, the VEGF production will be
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induced factor 1a. On the basis of pre-clinical data and different
mechanisms of anti-tumour activity of sorafenib and sirolimus, the
current phase I trial was performed with this combination. Special
attention was paid to the partly overlapping toxicity profiles and
the fact that both drugs are metabolized by CYP3A4. The primary
objective of this study was to identify the recommended dose
of the combination of sorafenib and sirolimus for subsequent
phase II studies. The secondary objectives were to (i) analyse
the pharmacokinetic (PK) profiles, (ii) determine the safety profile
(ii) determine the maximum tolerated dose (MTD) and (iv) evaluate
preliminary activity of the combination of sorafenib and sirolimus.
PATIENTS AND METHODS
Patient eligibility
Patients aged X18 years, with histologically or cytologically
confirmed advanced solid malignancies refractory to conventional
treatment or without any regular therapy option were enrolled.
Eligibility criteria included life expectancy X12 weeks, Eastern
Cooperative Oncology Group performance status p1, no previous
anti-cancer therapy within 4 weeks of study entry, no previous
treatment with sorafenib or sirolimus, adequate hematopoietic
(absolute neutrophil count X1.5 10
9l
 1;p l a t e l e t sX100 10
9l
 1),
hepatic (bilirubin p1.5 upper limit of normal (ULN), aspartate
transaminase/alanine transaminase p2.5 ULN, in case of liver
metastases p5 ULN,) and renal function (creatinine p2 ULN).
Patients with clinically symptomatic brain tumours or brain meta-
stases and patients with uncontrolled comorbidity were excluded.
The local ethics committee approved the study protocol. Written
informed consent was obtained from all patients before any study-
related procedures.
Study design and dose-escalation schedule
The recommended dose of the combination of sorafenib and
sirolimus was determined by dose escalation. Patients were
initially treated in cohorts of six per dose level. The number six
was chosen to achieve adequate PK profiling of the combination of
drugs, especially owing to the described large variances in
sirolimus PK parameters (MacDonald et al, 2000). Both drugs
were administered orally. Initially planned dose levels (DLs) were
as follows: DL 1 (starting DL): sorafenib 200mg b.i.d. and
sirolimus 2mg q.d., DL 2: sorafenib 400mg b.i.d. and sirolimus
2mg q.d., and DL 3: sorafenib 400mg b.i.d. and sirolimus 4mg q.d.
In case DL 1 would not be feasible, a DL 0 was defined with
sorafenib 200mg b.i.d. and sirolimus 1mg q.d. An extra inter-
mediate DL (DLim) was amended: DLim: sorafenib 400mg b.i.d.
and sirolimus 1mg q.d. During the first cycle, a run-in period
was used for optimal PK analysis of both single drugs as well as
to investigate the influence of sorafenib on sirolimus and vice
versa (Figure 1). Therefore, in the first cycle, sirolimus was
administered on day 1, once on day 16 and from day 21 as per
a daily continuous schedule, while sorafenib was administered from
day 5 on a daily continuous schedule. (Figure 1) The duration of one
cycle was 28 days. The dose limiting toxicity (DLT) period ended after
28 days of administration of combination of sorafenib and sirolimus,
thus 50 days after start of the study treatment. This prolonged DLT
period was chosen because of the expectation that the first 7 days
were needed to reach a steady concentration of sirolimus.
Patients remained in study medication for as long as the
investigator felt it was in their best interest and there was no
evidence of progressive disease (PD) or unacceptable toxicity.
Definition of MTD and dose-limiting toxicity
Toxicity was evaluated according to the common toxicity criteria
for adverse events (AEs) (CTCAEv3.0). The MTD was defined as
the highest dose at which none or one out of six patients developed
a DLT.
DLT was defined as any of the following events that was
determined to be possibly or probably related to sorafenib and/or
sirolimus and occurred during the first 50 days of treatment: any
non-haematological grade 3–4 toxicity with the exceptions of
nausea and vomiting, and fever that could be rapidly controlled
with appropriate measures, grade 4 neutropenia lasting for
X7 days or febrile neutropenia defined as absolute neutrophil
count p1.0 10
9l
 1 and fever X38.51C; grade 4 thrombocyto-
penia and grade 4 uncontrolled hypertension. The protocol was
amended to define that hypophosphatemia grade 3 or 4 was not a
DLT, as this is a well-known toxicity of sorafenib (Escudier et al,
2007).
Patient evaluation and follow-up
Toxicity assessment, haematology and clinical biochemistry were
performed at baseline and weekly during the first two cycles, and
thereafter once every 2 weeks. Full physical examination and
ECOG performance status were recorded at baseline and before
each new cycle. Concomitant medications were recorded at
every visit.
Response was evaluated according to the Response Evaluation
Criteria in Solid Tumours (Therasse et al, 2000) at baseline and
after every second cycle.
Pharmacokinetic assessments
Sorafenib is metabolized primarily in the liver and undergoes
oxidative metabolism, mediated by CYP3A4, as well as glucuroni-
dation by UGT1A9. The elimination half-life is 25–48h. Sirolimus
is a substrate for both CYP3A4 and P-glycoprotein. It is exten-
sively metabolized by O-demethylation and/or hydroxylation. The
terminal half-life in stable renal transplant recipients was 62±12h,
however, the effective half-life is shorter and the mean steady-state
concentrations are achieved after 5–7 days.
To evaluate the single-agent PK of sirolimus, blood samples
were obtained at 15 time points for up to 4 days after the first
administration, as follows: at baseline, 20 and 40min, and at 1, 2, 3,
Cycle 1
D56
          Sorafenib 2 b.i.d.
PK sampling
Sirolimus 1 q.d. D1 D5 D16 D21 D28
Cycle 2
Figure 1 Treatment schedule and pharmacokinetic (PK) schedule. The DLT period ended after 28 days of combination of sorafenib and sirolimus
administration, thus, 50 days after start of study treatment.
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day 1. On day 15, the PK of single-agent sorafenib was analysed by
collecting blood samples at baseline and 30min, at 1, 2, 4, 8, 10 and
12h after administration of sorafenib. To evaluate continuous dosing
of sorafenib combined with single-dose sirolimus, blood samples
were collected starting on day 16, when patients were already treated
with sorafenib since day 5 and single-dose sirolimus was added.
Samples were obtained at same time points after day 1 for sirolimus,
and at baseline after 30min and at 1, 2, 4, 8, 12 and 24h for
sorafenib. Fully validated LC/MS/MS assay methods were applied to
quantify blood concentrations of sirolimus and plasma concentra-
tions of sorafenib. Lower limits of quantization were 0.26mgl
 1 for
sirolimus and 0.01mgl
 1 for sorafenib.
On days 1 and 15 of the second cycle, samples were collected
to determine steady-state concentrations of sorafenib in plasma
and of sirolimus in blood after combined continuous dosing
at time points as follows: baseline, after 20, 30 and 40min, and
after 1, 2, 3, 4, 6, 8, 10 and 12h after administration. In this way, we
collected data of both drugs on PK of single-agent sirolimus,
single-agent sorafenib, effect of single-dose sirolimus on steady-
state level of sorafenib and effect of combination therapy
on steady-state plasma or blood levels. Peak plasma or blood
concentrations (Cmax), overall drug exposure (area under the
plasma concentration vs time curve; AUC) and terminal plasma
half-life (t1/2) were calculated using non-compartmental methods
according to the Bayer guideline ‘Harmonization of Data Evalua-
tion in Pharmacokinetics – A Task Force Report – ’ (1992 R-Report
No. R-5747 and 2000 Amendment A to Report No. R-5747).
A paired t-test on log-transformed values was used to calculate
changes in AUC, Cmax and t1/2.AP-value p0.05 was considered
significant.
RESULTS
General trial conduct
Between July 2007 and May 2009, 20 patients were screened for
inclusion in the trial. A total of 19 patients started treatment as one
patient had a screening failure because of the appearance of
clinically symptomatic brain metastases. Patient characteristics are
summarised in Table 1. Three patients had early PD within the
evaluation period of the first 50 days and were replaced as per
protocol. One patient was not evaluated for DLT owing to incorrect
medication intake by the patient herself. One patient (7%) received
one cycle, nine patients (60%) received two cycles, three patients
(20%) received four cycles and two patients (13%) received six
cycles. No relation between number of cycles received and DLs was
apparent.
Dose-limiting toxicities and MTD
On DL 1 (sorafenib 200mg b.i.d., sirolimus 2mg q.d.) three out
of six patients experienced a DLT. Two patients developed a
grade 3 elevation of aspartate transaminase, and one patient
a grade 3 elevation of alanine transaminase starting around day 28,
that is 7 days after starting the combination treatment. In one
patient this was accompanied by grade 3 fatigue, grade 3 anorexia
and grade 3 weight loss. In another patient experiencing a DLT,
grade 3 anorexia was also present. In all three patients, the
transaminases values returned to baseline levels after discontinua-
tion of sorafenib and sirolimus.
As this dose level was not tolerated, we decreased to DL 0
(sorafenib 200mg b.i.d., sirolimus 1mg q.d.). One out of six
patients had a DLT due to cardiac ischaemia. This 49-year-old
female patient with controlled hypertension and a chondro-
sarcoma presented on day 48 of the study, with chest pain due
to cardiac ischaemia. A coronary angiography showed a small
occlusion of the left coronary artery due to arterial thrombosis,
and apical ballooning. The patient discontinued the study
medication and recovered completely.
As DL 0 was tolerated, we amended the protocol to escalate to
an DLim (sorafenib 400mg b.i.d., sirolimus 1mg q.d.), as the
registered regular dosing of sorafenib is 400mg b.i.d. On this DLim,
three out of four patients experienced a DLT. All three patients
experienced a grade 3 palmar–plantar erythrodysaesthesia (PPE,
also called ‘hand–foot syndrome’; Figure 2), in one patient
accompanied with grade 3 acneiform dermatitis (Figure 2).
One of the patients also had a grade 3 fatigue. In all three patients,
the PPE recovered completely after discontinuation of the study
drugs. Consequently, the MTD was established as sorafenib 200mg
b.i.d. and sirolimus 1mg q.d.
Overall safety and tolerability
Adverse events and serious AEs. All patients experienced several
AEs. Table 2 summarizes AEs occurring with a frequency 430% or
grade 3 or worse. The most frequently reported AEs were elevated
aspartate transaminase and alanine transaminase (95% and 63%),
anaemia (89%), hypophosphatemia (84%), anorexia (80%), cough
(79%), fatigue (79%), PPE (69%), nausea (68%) and diarrhoea (68%).
Table 1 Patient characteristics (n¼19)
Age, median (range) 49 (28–64)
Male/female 11/8
Performance score
0 14 (74%)
1 5 (26%)
Tumour type
Sarcoma 8 (42%)
Colorectal cancer 3 (16%)
Melanoma 2 (11%)
Non-small cell lung cancer 2 (11%)
Hepatocellular carcinoma 2 (11%)
Thyroid cancer 1 (5%)
Breast cancer 1 (5%)
Previous treatment 19 (100%)
Systemic treatment
Chemotherapy 15 (79%)
Targeted therapy 3 (16%)
Hormonal treatment 2 (11%)
Surgery 17 (89%)
Radiotherapy 9 (47%) Figure 2 Left panel: Plantar palmar erythrodysaesthesia (PPE, also called
‘hand foot syndrome’). Right panel: Acneiform dermatitis.
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and PPE was high in the first 50 days on study treatment, and
increased significantly during prolonged study participation. Most
patients had a combination of several grade 1–3 toxicities. There-
fore, the combination therapy was intolerable for most patients.
Liver test abnormalities. Abnormalities in hepatic function tests
were frequently observed, especially on DL 1. As early as 1 week
after the combined dosing, elevation of aspartate transaminase and
alanine transaminase were observed with peak values between days
28–42 (2–4 weeks of combination therapy). Two of the three
patients with grade 3 elevations of transaminases suffered from
hepatocellular carcinoma and had baseline transaminase values
between 1.0–2.5 ULN. The third patient had colorectal cancer
without liver involvement and with a normal hepatic function at
baseline. In these three patients, hepatic function restored to
baseline after cessation of therapy within weeks. Furthermore,
recovery of hepatic function was also observed in patients with less
enhanced elevations of transaminases, who did not interrupt the
combination treatment, generally between 2–6 weeks after
measurement of peak liver function abnormalities.
Cutaneous toxicity. PPE, maculopapular rash, acne, pruritis and
dry skin were the frequently reported AEs with combined
sorafenib and sirolimus. In general, skin toxicity was mild.
However, on the DLim, severe PPE and rash occurred, generally
starting within 10 days after initiation of the combination therapy.
The patients experienced a painful red skin, scaling with yellowish
demarcations (Figure 2). Emollients did provide some relief,
although short drug interruptions of 3–5 days were needed for full
clinical recovery. In two patients, sorafenib was reinitiated at a
lower dose of 200mg b.i.d., but one of them had a recurrence, after
which we permanently discontinued the sorafenib in this patient.
Pharmacokinetics
The effect of sirolimus on sorafenib PK. On average, concomitant
administration of single oral doses of 1mg or 2mg of sirolimus did
not influence AUC(0 12h) (P¼0.67) and Cmax (P¼0.96) of
sorafenib following multiple dosing with 200mg b.i.d. of sorafenib.
In the DLim, when 1mg sirolimus was administered together with
400mg b.i.d. of sorafenib, minor non-significant mean decreases
in both parameters by 15% (P¼0.14) and 8% (P¼0.57) were
observed. (Table 3)
The effect of sorafenib on sirolimus PK. On DL 1, pre-treatment
with multiple oral doses of 200mg b.i.d. sorafenib resulted in a mean
decrease of Cmax of sirolimus by 55% (P¼0.006), while the
AUC(0 96h) of sirolimus non-significantly decreased by 37%
(P¼0.125) and the mean terminal half-life of sirolimus remained
unchanged (P¼0.66). Similarly, on the DLim, the Cmax decreased on
average by 55% (P¼0.027) and the AUC(0 96h) by 25% (P¼0.363).
This is in contrast to results from patients on DL 0, in which no
change in the mean AUC(0 96h) of sirolimus was observed (P¼0.955)
on simultaneous administration of both drugs, and Cmax was only
non-significantly reduced by 18% (P¼0 . 5 1 5 )o na v e r a g e( T a b l e4 ) .
Table 2 Haematological and non-haematological adverse events occurring in 430% of patients or reaching grade 3–4 severity. (n¼19)
DLT period (first 50 days) All cycles
Adverse event Grade 1 (n) Grade 2 (n) Grade 3 (n) Grade 4 (i) All (%) Grade 1 (n) Grade 2 (n) Grade 3 (n) Grade 4 (n) All (%)
Haematological adverse events
Anaemia 9 4 0 0 68 9 8 0 0 89
Neutropenia 0 2 0 0 11 4 2 0 0 32
Non-haematological adverse events
Anorexia 7 0 2 0 47 7 6 2 0 79
Nausea 7 3 0 0 53 8 5 0 0 68
Vomiting 2 1 1 0 21 7 1 1 0 47
Dysphagia 4 0 0 0 21 6 0 1 0 37
Diarrhoea 5 4 0 0 47 7 5 1 0 68
Constipation 3 0 0 0 16 6 0 0 0 32
Weight loss 5 0 1 0 32 7 1 1 0 47
Fatigue 2 6 2 0 53 2 8 5 0 79
Acne 4 1 1 0 32 2 1 1 0 32
Dry skin 6 1 0 0 37 8 1 0 0 47
Rash 4 2 0 0 32 6 4 0 0 53
PPE 6 2 3 0 58 6 2 5 0 68
Alopecia 3 1 0 0 21 9 1 0 0 53
Hoarseness 5 1 0 0 32 6 1 0 0 37
Cough 11 1 0 0 63 14 1 0 0 79
Dyspnoea 7 0 0 0 37 8 0 0 0 42
Abdominal pain 5 4 0 0 47 6 6 0 0 63
Thoracic pain 1 0 0 0 5 7 1 0 0 42
Dizziness 5 0 0 0 26 6 0 0 0 32
Hypertension 1 1 4 0 32 1 1 5 0 37
Cardiac ischaemia 0 0 0 1 5 0 0 0 1 5
Sensory neuropathy 6 0 0 0 32 7 1 0 0 42
Elevated AST 10 2 3 0 79 12 3 3 0 95
Elevated ALT 9 1 1 0 58 10 1 1 0 63
Elevated bilirubin 2 3 0 0 26 3 3 0 0 32
Hypoalbumin 3 5 0 0 42 4 6 1 0 58
Hypophosphatemia 0 11 4 0 79 0 12 4 0 84
Hypokalemia 7 0 0 0 37 9 0 0 0 47
Hypercholesterolaemia 7 1 0 0 42 7 2 0 0 47
Hypertryglyceremia 4 2 0 0 32 6 2 0 1 47
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase.
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In all, 14 patients were evaluated for response after two cycles. No
objective responses were observed. Six patients had PD at the first
evaluation after 8 weeks (two cycles). Of the eight remaining
patients, two patients with stable disease decided to stop after 9
and 18 weeks of study participation because of the considerations
on the quality of life based on multiple grade 1–2 toxicities. One
other patient had to stop after 8 weeks because of cardiac
ischaemia, which was a DLT in the last few days of the DLT period.
Of the remaining four patients, two showed PD after 16 weeks
(four cycles) and two after 24 weeks (six cycles).
DISCUSSION
This phase I study investigates the combination of two oral small
molecule signal transduction inhibitors each targeting different
pathways, namely the RAS-RAF-MEK-ERK and VEGF pathway
(sorafenib) and the phosphatidyl-inositol 3-kinase/Akt pathway
(sirolimus). In this study, the combination of sorafenib and sirolimus
caused enhanced toxicity with only modest clinical activity.
The recommended dose was established on sorafenib 200mg
b.i.d. and sirolimus 1mg q.d. This is 50% below the recommended
dose for single-agent therapy with sorafenib. For sirolimus, as an
anti-cancer therapy, no regular dosing is known, although reports
mention effective doses between 0.5 and 10mg daily (Stallone et al,
2005; Reardon et al, 2006; Rizell et al, 2008). The PK results did not
provide a clarification for the observed enhanced toxicity.
The observed toxicity of the combination of sorafenib and
sirolimus was impressive. This is illustrated by Table 2, showing
high frequencies of toxicities, which accumulated during pro-
longed study participation. The impact of the ongoing combi-
nation of several toxicities, even when relatively mild as grade
1 or 2, on the quality of life of the participating patients was high.
Enhanced toxicity is observed in several other combinations
of targeted therapies. A recent phase I study, which combined
sorafenib with monoclonal VEGF antibody bevacizumab reported
enhanced toxicity, including transaminitis grade 2–4 in 13 out
of 39 patients (33%) and PPE in 31 out of 39 patients (79%, in
23 patients grade X2; Azad et al, 2008) Like in our study, the
MTD of this combination was below single-agent therapy doses
with sorafenib 200mg b.i.d. and bevacizumab 5mgkg
 1 intra-
venously once in every 2 weeks. The same group studied inter-
mittent dosing of sorafenib with bevacizumab, which was tolerated
better (Lee et al, 2010). In two preliminary reports of studies
combining sorafenib with mTOR inhibitor temsirolimus, signi-
ficant toxicity was described including mucocutaneous toxicity,
serum transaminase elevations, hypertrygliceridemia and throm-
bocytopenia (Patnaik et al, 2007; Kim et al, 2009). In the first
study, the MTD was sorafenib 400mg and 200mg daily with
temsirolimus 25mg intravenously every week. (Kim et al, 2009)
In the second study, the MTD was not yet determined, although
the DLs combining sorafenib 400mg b.i.d. with temsirolimus
25mg intravenously every week were not tolerated and lower doses
of sorafenib were under study (Patnaik et al, 2007). In contrast
to these observations, three preliminary studies reported the
combination of sorafenib and mTOR inhibitor everolimus as
tolerable and safe, as did one preliminary report of a phase I study
with the combination of sorafenib and temsirolimus (Giessinger
et al, 2008; Cen et al, 2009; Harzstark et al, 2009; Wen et al, 2009).
Two studies combined sunitinib with temsirolimus. In one of
them, PPE and fatigue were common AEs. The other study was
terminated because of substantial toxicity (Li et al, 2009; Patel
et al, 2009).
We can only speculate about the reasons for the enhanced
toxicity. Toxicities of targeted therapies might be because of the
inhibition of multiple so-called ‘off-targets’; elements in the path-
ways that are not the primary target of a tyrosine kinase inhibitor.
Both specific targets as well as off-targets do have a normal
physiological function, for example the survival of endothelial cells
and the maintenance of vascular integrity. The combination of
several targeted agents enhances the number of elements within the
pathways that are influenced, which might explain the enhanced
toxicity (Gotink and Verheul, 2009). Furthermore, in a ‘vertical
strategy’, drugs are combined to inhibit a cascade of signalling
molecules. Here applied combination of mTOR inhibitor sirolimus
and VEGFR inhibitor sorafenib is an example for this approach
(Sosman and Puzanov, 2009). By inhibition in a ‘vertical’ strategy,
feedback loops in the network of signalling pathways might be
involved in unexpected and undesirable outcomes of targeted
therapies (Gotink and Verheul, 2009). Another interesting factor
involved in toxicity might be an altered pharmacodynamic effect of a
tyrosine kinase inhibitor owing to polymorphisms in specific genes
encoding for metabolizing enzymes, efflux transporters and drug
targets, as is observed for sunitinib (van Erp et al, 2009). The
combination of several targeted therapies with overlapping meta-
bolic profiles may enhance gene vulnerability.
In this study, the most occurring dose-limiting toxicities were
serum transaminase elevations and PPE. Both toxicities have been
reported before in combination strategies with mTOR inhibitors
and VEGF(R) inhibitors (Patnaik et al, 2007; Azad et al, 2008, 2009;
Kim et al, 2009). However, for both sorafenib and sirolimus, serum
transaminase elevations are not a frequently reported AE (Bhojani
et al, 2008). The timing of the rise in serum transaminases
2–3 weeks after start of the combination and the recovery after
discontinuation of the combination, suggest a causal relationship.
Vascular endothelial growth factor has a role in structural,
functional integrity of the liver. Most consistently, growth stimulat-
ing, regenerative and cytoprotective effects of VEGF and a VEGFR
agonist have been found in pre-clinical models of ischaemia and
reperfusion-induced hepatic toxicity, indicating a causal relation-
ship between VEGFR inhibitors and transaminitis (Eskens and
Verweij, 2006). Analysis of skin biopsies of PPE patients indicate
that epidermal cells are swollen, capillaries are dilated and apoptotic
endothelial cells are present. This suggests that the skin toxicity is
a direct consequence of the biological activity of VEGFR inhibitors
(Faivre et al, 2006). Other observed cutaneous toxicities were
maculopapular rash, acne, pruritis and dry skin. These are well
known AEs of oral VEGFR inhibitors. (Lee et al,2 0 1 0 ) .
The clinical efficacy observed in our study was only moderate,
with stable disease in 53% of patients but only in 14% persisting
for more than 4 months. The patients participating in this study
were heavily pre-treated and had PD at the time of enrolment.
In conclusion, the MTD of the combination is sorafenib 200mg
b.i.d. and sirolimus 1mg q.d. This combination showed enhanced
toxicity, which could not be explained by the influence of the PK of
each targeted agent. We do not recommend further exploration of
this dosing schedule. Pre-clinical research focusing on the causes
of enhanced toxicity of these combination therapies is highly
warranted.
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